The drug, ATryn has already been approved in Europe. Up until now the drug has been created from blood from human donors. The drug is used to prevent blood clots and would be used during surgery given via an IV, and would not replace normal prescribed blood thinners taken as a normal treatment...
This article states part of the reporting system will include information on the willingness of a doctor to use genetic testing, well first of all we need to help the doctors to bring this full circle with the integration into the clinical side of this, as I have spoken to many MDs and they are aware...
It seems not a week goes by without a warning being issued from the FDA, so this looks to be a sign of the times, not to put anyone out of business, but to create an awareness. This is transparency folks and the warnings will keep on coming, so get used to it. Who knows, perhaps the competition...
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing